Get the Stockscreener App
2.06
5.64%
0.11
After Hours:
1.96
-0.10
-4.85%
Equillium Inc stock is traded at $2.06, with a volume of 174.71K.
It is up +5.64% in the last 24 hours and up +12.57% over the past month.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
See More
Previous Close:
$1.95
Open:
$1.95
24h Volume:
174.71K
Relative Volume:
0.26
Market Cap:
$125.44M
Revenue:
$4.39M
Net Income/Loss:
$-24.42M
P/E Ratio:
-3.259
EPS:
-0.6321
Net Cash Flow:
$-22.92M
1W Performance:
-3.29%
1M Performance:
+12.57%
6M Performance:
+47.14%
1Y Performance:
+158.79%
1-Day Range:
$1.9007
$2.06
1-Week Range:
$1.9007
$2.285
52-Week Range:
$0.27
$2.70
Equillium Inc Stock (EQ) Company Profile
Name
Equillium Inc
Sector
Industry
Phone
(858) 412-5302
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Compare EQ vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EQ
Equillium Inc
|
2.06 | 118.74M | 4.39M | -24.42M | -22.92M | -0.6321 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Equillium Inc Stock (EQ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-26 | Initiated | Roth Capital | Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Mar-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-29-21 | Resumed | Stifel | Buy |
| Sep-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-14-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-10-20 | Resumed | Stifel | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
View All
Equillium Inc Stock (EQ) Latest News
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in Equill - GuruFocus
Equillium Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Equillium Inc. (NASDAQ:EQ) Reports In-Line Q4 Earnings, Highlights Pipeline Progress and Runway into 2029 - ChartMill
Equillium (EQ) Secures Financial Path to 2029, Focuses on Key Dr - GuruFocus
Equillium (NASDAQ:EQ) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
EQUILLIUM ($EQ) Releases Q4 2025 Earnings - Quiver Quantitative
Equillium (NASDAQ: EQ) expands autoimmune pipeline and raises $65M in private financings - Stock Titan
Equillium (EQ) shifts to EQ504 focus, raises $85M and funds into 2029 - Stock Titan
Equillium says cash can fund ulcerative colitis drug push into 2029 - Stock Titan
Here’s What Roth Capital Thinks of Equillium (EQ) Stock - Yahoo! Finance Canada
Equillium Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
RA Capital group reports 9.9% stake in EQ (NASDAQ: EQ) via warrants - Stock Titan
Macro Review: What is the target price for Equillium Inc stock2026 Earnings Impact & Daily Profit Focused Screening - baoquankhu1.vn
Equillium (EQ) Expected to Announce Earnings on Thursday - MarketBeat
Equillium, Inc. Hits New 52-Week High of $2.62, Up 249% - Markets Mojo
Equillium to Participate in the 38th Annual Roth Conference - Bitget
Biotech Equillium set for Roth fireside chat, investor talks - Stock Titan
Risk Recap: Can Equillium Inc reach all time highs this year2026 Intraday Action & Expert Approved Momentum Ideas - baoquankhu1.vn
Equillium, Inc. Hits New 52-Week High of $2.70, Up 228% Yearly - Markets Mojo
Equillium (NASDAQ:EQ) COO Sells $300,780.00 in Stock - MarketBeat
Equillium (EQ) SVP Zedelmayer sells $300k in shares By Investing.com - Investing.com Canada
Equillium (EQ) SVP Zedelmayer sells $300k in shares - Investing.com
Equillium (EQ) COO exercises options and sells 120,312 shares under plan - Stock Titan
This analyst loves Equillium - Cantech Letter
Cantor Fitzgerald L. P. Invests $608,000 in Equillium, Inc. $EQ - MarketBeat
Equillium Strengthens Financial Position with New Investments - StocksToTrade
Equillium: $35 Million Raised For Biotech Therapy Development - Pulse 2.0
Equillium (NASDAQ:EQ) Coverage Initiated at Roth Mkm - Defense World
Analysts Are Bullish on Top Healthcare Stocks: Equillium (EQ), Qiagen (QGEN) - The Globe and Mail
Equillium (NASDAQ:EQ) Raised to "Hold" at Wall Street Zen - MarketBeat
Equillium secures $35M financing from RA Capital Management By Investing.com - Investing.com South Africa
Equillium secures $35M financing from RA Capital Management - Investing.com Australia
Proposed resale of 120,312 EQ shares reported (EQ) - Stock Titan
EQ SEC FilingsEquillium 10-K, 10-Q, 8-K Forms - Stock Titan
Equillium (EQ) Secures $35 Million Through RA Capital Management Investment - GuruFocus
Equillium (EQ) Receives Buy Rating from Roth Capital | EQ Stock News - GuruFocus
Roth Mkm Initiates Coverage on Equillium (NASDAQ:EQ) - MarketBeat
Equillium, Inc. (NASDAQ:EQ) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Equillium Raises Capital Through Private Equity Securities Sale - TipRanks
Equillium Enters Into $35 Million Securities Purchase Agreement With RA Capital Management - marketscreener.com
Equillium Announces $35 Million Financing with RA Capital Management - Bitget
Equillium Raises $35 Million in Private Placement With RA Capital - TradingView
Equillium (EQ) to raise $35.0 million via shares and pre-funded warrant - Stock Titan
Equillium Secures $35 Million Funding Commitment from RA Capital to Advance EQ504 Clinical Development - Quiver Quantitative
Roth/MKM initiates Equillium stock with buy on ulcerative colitis drug - Investing.com Australia
Form 144 Equillium For: 13 March By Investing.com - Investing.com Canada
Equillium SVP Zedelmayer sells $328k in shares By Investing.com - Investing.com Australia
Equillium SVP Zedelmayer sells $328k in shares - Investing.com
Equillium (NASDAQ:EQ) COO Sells $362,438.00 in Stock - MarketBeat
Equillium (EQ) COO exercises options, sells 185,937 pre-planned shares - Stock Titan
Equillium (EQ) COO exercises options, sells 181,219 shares under 10b5-1 plan - Stock Titan
Equillium Inc Stock (EQ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):